Former senior adviser at Firmenich SA
- Likely rationale for announced DSM-Firmenich (AMS: DMS) merger, synergy targets and operational outline
- Integration timeline, execution risks and focus
- Potential competitive landscape impact, highlighting Givaudan (VTX: GIVN), Symrise (ETR: SY1), International Flavors & Fragrances (NYSE: IFF) and Kerry (LON: KYGA)
- Expected changes in customer buying behaviour, supply chain considerations and EBITDA outlook
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.